苯达莫司汀联合利妥昔单抗治疗胃外复发黏膜相关淋巴组织淋巴瘤

摘要

目的 探讨利妥昔单抗联合苯达莫司汀(R-Benda)治疗胃外复发黏膜相关淋巴组织淋巴瘤(MALT淋巴瘤)的疗效.方法 回顾性分析接受R-Benda方案化疗的10例诊断为复发胃外的MALT淋巴瘤患者临床资料.9例患者分别在化疗第2天和第3天接受90 mg/m2苯达莫司汀,1例患者因体能原因接受70 mg/m2苯达莫司汀;所有患者均在第1天接受375 mg/m2利妥昔单抗治疗;21 d为1个疗程.结果 8例患者接受了6个疗程化疗,1例患者因个人原因仅接受5个疗程化疗,另外1例老年患者在接受3个疗程化疗后疾病进展.8例患者达到了完全缓解,1例患者达到了部分缓解,另外1例老年患者在化疗4个疗程后因疾病进展而死亡.患者主要存在血液学不良反应事件,但程度较轻.中位随访24个月(5～43个月),9例患者生存,其中8例处于疾病缓解期.结论 R-Benda方案治疗胃外复发MALT淋巴瘤疗效好,而且不良反应轻.%Objective To investigate the rituximab plus bendamustine (R-Benda) therapeutic effect for relapsed extragastric mucosa-associated lymphoid tissue (MALT) lymphoma.Methods Ten patients (three females and seven males) with relapsed extragastric MALT lymphoma undergoing therapy with R-Benda were defined.Bendamustine was given at a dose of 90 mg/m2 on days 2 and 3 in nine patients and at 70 mg/m2 in one patient, while all received 375 mg/m2 rituximab on day 1.Results Nine patients received six courses of therapy,while one patient discontinued therapy after five courses for personal reasons, while one elderly patient had progressive disease after three courses.Tolerance of therapy was excellent, and all except one patient responded.Eight patients achieved the complete remission, one achieved the partial remission, and one patient progressed.Toxicities were mild and mainly hematological.After a median follow-up of 24 months (range, 5-43 months), 9 patients were alive.Conclusion R-Benda regime has high activity and good tolerance for patients with relapsed extragastric MALT lymphoma.